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CELLULAR AND MOLECULAR EFFECTS OF FIBROBLAST GROWTH 
FACTORS 2 AND 4 ON HUMAN UMBILICAL VEINULAR ENDOTHELIAL 
CELLS 
 
KHALED WALLY KABBARA 
ABSTRACT 
  
Fibroblast growth factors (FGFs), encompasses a family of 22 related 
polypeptide. There are 18 different biologically active FGF proteins. They influence a 
wide array of biological and physiological responses such as migration, proliferation, 
tissue homeostasis, and wound healing.  Most FGF are secreted and bind to heparin 
sulphate binding proteins (HPSG) in the extra cellular matrix (ECM). FGF-binding 
protein (FGF-BP) is a chaperon protein that binds to FGF releasing from the ECM and 
chaperoning it to bind to FGF receptors (FGFRs). FGFR dimerize when bound to FGF 
and starts series of a signal cascade that ultimately leads to the activation of MAPK. 
FGF2 and FGF4 are selected from the pool of 18 different FGF to be studied in this 
investigation. Both FGF2 and FGF4 have been reported to be critical for development 
during embryogenesis. De-regulation of these proteins could lead to various pathologies 
including different types of cancers. Hence we attempt to investigate the cellular and 
molecular role of these proteins and their implication on cells in an attempt to set up a 
foundational understanding for further studies that will include FGF-BPs and FGFRs. To 
do so, we used HUVECs to examine FGF2 and FGF4 activity through Western Blot 
	  	   vii 
analysis. We also investigated their effect on migration using the ECIS Migration Assays, 
on wound healing by the ECIS Wound Healing Assays and captured wound healing 
images through Incucyte. Data from these experiments indicated that both, FGF2 and 
FGF4, have a role in cellular migration and wound healing. They also show they have a 
dose response on these cells. As a result, we can use these models to further investigate 
FGF2 and FGF4 modulation by FGF-BP1 and FGF-BP3 and the affects cellular response.  
 
 
 
.   
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INTRODUCTION 
 
 Fibroblast Growth Factors (FGF) encompasses a family of 18 structurally related 
heparin-binding proteins which has a wide variety of cellular and physiological effects. 
FGFs have a critical role in embryonic development, tissue homeostasis, repair, and 
regeneration. Compromised levels of FGFs due to mutation or irregular expression levels 
would results in different pathologies including cardiovascular and metabolic disorders in 
addition to cancer.  (Tassi et al., 2001) 
Based on phylogenetic analysis, FGFs consist of 18 biologically active ligands 
divided into seven families (Figure 1).  Most of the FGFs act in a paracrine fashion with 
the exception of FGF19, FGF21 and FGF23, which act as hormones. (Itoh and Ornitz, 
2011) 
 FGFs are excretory proteins. Upon secretion most FGFs are sequestered in the 
extracellular matrix (ECM) bound to heparin sulphate proteoglycans (HPSG) and 
therefore not bioavailable. The activities of heparinases, proteases or the interaction with 
secreted fibroblast growth factor binding proteins (FGF-BPs) are proposed mechanisms 
of FGF release from the extracellular milieu. (Turner and Grose, 2010;Tassi et al., 2001)  
FGF-BPs (BP1, 2, and 3) are secreted proteins and are highly conserved among 
different species although FGF-BP2 gene is absent from the mouse genome. FGF-BP1 is 
the most characterized member of the FGF-BP family. FGF-BP1 exhibits low expression 
levels in most adult human and mouse tissues. However it plays a critical role in 
embryonic development where its expression is tightly regulated (Abuharbeid et al., 
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2005). FGF-BP1 also enhances wound-healing angiogenesis by enhancing FGF activity 
(Abuharbeid et al., 2005). 
Irregular expression of FGF-BP1 is linked to different pathologies. Its presence 
could be an indicator of early stages of pancreatic and colorectal adenocarcinoma (Tassi 
and Wellstein, 2006). Squamous cell carcinoma (SCC) and colorectal cancer exhibit a 
high expression level of FGF-BP1, and high amounts of microvessels (Abuharbeid et al., 
2005). Studies show that growth and angiogenesis of xenograft tumors in mice is 
decreased when FGF-BP1 is reduced. FGF-BP1 has been characterized as an angiogenic 
switch molecule, necessary for angiogenesis (Czubayko et al., 1997) 
FGF-BP1 acts as a chaperone protein mediating the mobilization of FGFs from 
HSPGs in the ECM and modulating FGFs activity by increasing their affinity to FGFR 
(Tassi et al, 2001). FGFs bind specifically to four trans-membrane tyrosine kinase 
receptors namely FGFR1-4 (Turner and Grose2010).  This binding results in the FGFR 
dimerization and trans-phosphorylation of the intracellular kinase domain, thereby 
eliciting a downstream signaling cascade. (Mohammadi et al., 2005). These 
phosphorylated tyrosine domains act as docking sites for adaptor proteins that can also be 
phosphorylated by the kinases activity, leading to a signal transduction cascade ultimately 
resulting in the activation of important kinases via phosphorylation. Such kinases in the 
pathway include mitogen-activated protein kinase (MAPK)/ extracellular signal-related 
kinase 1 /2  (ERK1/2), AKT, and p38. Activation of FGFR signaling pathway leads to an 
increase in cell survival, proliferation, migration, invasion, and angiogenesis (Turner and 
Gross, 2010).   
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In this study, we focus on investigating the effects of FGF2 and FGF4 on cellular 
responses using primary human umbilical vein endothelium vascular cells (HUVECs) as 
a model.  Our aim is to use different assays to understand the cellular responses triggered 
by FGF4 and FGF2.  
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Figure1: Human FGF Evolutionary relationship Tree:  
Based on phylogenetic analysis, there are 22 FGF genes arranged in to 7 families 
based on their evolutionary relationships. The lengths of the lines represent the 
evolutionary distance. (Itoh and Ornitz, 2011) 
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BACKGROUND 	  
Fibroblast Growth Factors 2 and 4: FGF2	  is	  one	  of	  the	  most	  extensively	  studied	  FGFs.	  It	  was	  first	  isolated	  as	  mitogen	  from	  brain	  and	  neck	  tumors.	  FGF2	  is	  a	  secretory	  protein	  that	  binds	  to	  HPSG	  and	  resides	  in	  the	  ECM.	  The	  mechanism	  of	  secretion	  is	  not	  yet	  fully	  understood	  but	  one	  proposed	  method	  of	  exit	  depends	  on	  passive	  processes	  such	  as	  wounding,	  cell	  death,	  or	  chemical	  injury.	  Factors	  such	  as	  fibrin-­‐split	  products	  are	  also	  thought	  to	  promote	  the	  release	  of	  FGF2	  from	  cells.	  In	  addition,	  endothelial	  cells	  are	  induced	  to	  release	  FGF2	  upon	  exposure	  to	  polymorphonuclear	  leukocytes,	  however	  the	  mechanism	  is	  unclear	  yet	  (Bikfalvi	  et	  al.,	  1997).	  
Most	  developing	  and	  adult	  human	  tissues	  such	  as	  brain,	  heart,	  lung,	  skeletal	  muscle,	  pancreas	  among	  others,	  express	  FGF2.	  In	  addition,	  FGF2	  is produced in the 
entire epiphyseal growth plate (Chlebova et al., 2011). It also plays a role in limb 
formation during embryogenesis (Detillieux et al., 2003). Mice with the FGF2 gene 
knockout although viable, exhibit loss of vascular tone, and loss of neurons in deep 
cortical layers. They also show impaired recovery from injuries to the heart (Itoh and 
Ornitz JBC 2011).  
FGF4 shares 43% of its amino acids sequence with FGF2 ( Kosaka and Ochiya et 
al., 2008). FGF4 is expressed early in development and plays critical roles at different 
stages of embryogenesis (Lu et al.,2005; Obokata et al. 2014). FGF4 knockout mice, 
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however, fail to form blastocysts at the embryo level hence they die at an early stage of 
embryogenesis (Itoh & Ornitz, 2010).  FGF4 serves as a strong chemoattractant, driving 
streak cells to migrate towards it.(Yang et al., 2002 Dev. Cell). In addition, FGF4 induces 
limb development in embryos (Lu et al., Development 2005), maintains pluripotency in 
embryonic stem cells, maintains self-renewal of stem cells in trophectoderm and induces 
myotome development (Kosaka et al., 2009) 
FGF4 is also found in adult tissues, predominantly in the nervous system, 
intestines, and testis. FGF4 is also detected in the spleen, bone marrow, kidneys, lungs, 
eyeball, and tongue (Kosaka et al., 2009). In adult tissues, FGF4 induces angiogenesis, 
proliferation and differentiation of neuronal stem cells, production of platelets through 
megakaryopoiesis, and stimulation of Sertoli-Germ cell interaction in spermatogenesis 
(Kosaka et al., 2009). 
 
Cellular Function of Fibroblast Growth Factor 2 & 4 and Disease:  
 FGF2 plays an important role in many cellular functions such as proliferation, 
differentiation, survival, adhesion, migration, motility, apoptosis, and enhances wound 
healing and angiogenesis in both vivo and vitro. FGF2 is a chemoattractant for venular 
endothelial cells (Barkefors et al., 2008) and cell migration depends on the activation of 
MAPK by the binding of FGF2 to FGFR (Pintucci et al., 2002; Shono et al., 2001). FGF2 
cellular functions contribute to pathology such as cancer and atherosclerosis (Fang et al 
2003). 
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FGF4 also promotes angiogenesis, proliferation, and cell migration in cells 
(Kosaka et al., 2009) FGF4 is also an oncogene and imbalance of FGF4 level is 
associated with many tumors and cancers. FGF4 mediates growth in testicular germ cell 
tumors and it is expressed in one third of primary germ tumors (Kosak et al., 2009). 
Moreover, FGF4 angiogenic activity is associated with progression towards a metastatic 
phenotype in mouse mammary carcinoma (Deroanne et al., 1997). Several other tumors 
are caused by amplification in FGF4 levels such as Kaposi’s carcinoma. FGF4 is also 
observed in esophageal carcinomas, primary tumors, and metastatic tumors (Kosaka et 
al., 2009). FGF4 elicits angiogenic responses, cell proliferation and differentiation ( 
Deroanne et al., 1997; Kosaka et al., 2009). FGF4 mediates angiogenesis through 
autocrine upregulation of vascular endothelial growth factor expression (VEGF) 
(Deroanne et al., 1997). 
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SPECIFIC AIMS  
FGF2 and FGF4 have critical roles in tissue homeostasis.  Aberrant levels of 
expression leads to pathology including cancer (REF). The purpose of the current study is 
to optimize and study the effect of these proteins using HUVECs as a model. To the best 
of our knowledge, HUVEC cells have not been used before to study the role of FGF2 and 
FGF4 specifically on migration and wound healing. Specifically we will: 
i. Evaluate the activity of FGF2 and FGF4 and the ability to bind and 
stimulate HUVEC cells using Western Blot following treatment 
with FGF4 at 1ng/ml, 5ng/ml, 10ng/ml and 25ng/ml, and by FGF2 
at 1ng/ml and 5ng/ml. 
ii. Evaluate migration and chemotaxis using ECIS Migration Assays 
in HUVEC cells following treatment with FGF4 at 1ng/ml 5ng/ml, 
10ng/ml and 25ng/ml, and by FGF2 at 1ng/ml and 5ng/ml .  
iii. Evaluate wound healing and cell motility by ECIS Wound Healing 
Assay in HUVEC cells following treatment with FGF4 at 1ng/ml, 
10ng/ml and 50ng/ml and by FGF2 at 1ng/ml, 10ng/ml and 
50ng/ml. 
iv. Evaluate Wound healing and cell motility by imaging (Incuctye) of 
HUVEC cells following treatment with FGF4 at 1ng/ml, 3ng/ml, 
and 10ng/ml, and by FGF2 at 1ng/ml and 10ng/ml. Data from. The 
imaging generates time-lapse photographs of cells. 
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We expect FGF4 and FGF2 to influence migration and wound healing through 
motility in HUVEC cells. The study should generate an idea at what concentrations of 
FGF2 and FGF4 should be used for optimal results.  We will also gain important 
comparative insights between the specific function of FGF2 and FGF4 and their potency 
on HUVEC cells using these techniques. To the best of our knowledge, this experimental 
model using the techniques used in this study has not been investigated before. Insights 
gained as a result of this study will serve as a platform for further investigations such as 
in the modulation of FGF2 and FGF4 by FGF-BP1 and FGF-BP3 on cell responses.  
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METHODS  
  
Cell Culture:  
Primary human umbilical vein endothelial cells (HUVECs) were maintained in 
endothelial growth medium-2 (EGM) (Lonza Inc., Walkersville, MD) supplemented with 
2% fetal bovine serum as recommended by the supplier. 
Fibroblast Growth Factors 
FGF4: Peprotech (Rocky Hill, NJ) reconstituted according to manufacturer. (Cat# 100-
31; Lot# 1109171). 
FGF2 (Basic Fibroblast Growth Factor bFGF): Life Sciences (Fredrick, MD). 
Reconstituted according to manufacturer. (Publication Part Number: MAN0001172) 
Western Blot Analysis 
HUVECs are grown in T75 flask in the presence of EGM until they reach 80% 
confluence. Cells are then removed from the flask, resuspended in 15ml EGM. Cell 
suspension (1 ml)  is then seeded in each of the 100mm x 20mm style, polystyrene 
treated, non-pryogenic cell culture dishes (Corning 430167) containing 9ml  of EGM. 
After 24 hours, EGM is removed; cells are washed twice with phosphate buffered saline 
(PBS) and replaced with endothelial basal medium (EBM) for starvation. Cells are 
starved for 4 hours then stimulated with 1ng/ml, 5ng/ml, 10ng/ml, 25ng/ml of FGF4 or 
1ng/ml and 5ng/ml of FGF2. Cells are also stimulated with EGM as positive control and 
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EBM as negative control. Cell lysate proteins are separated by gel electrophoresis. 
Phosphorylated MAPK is detected by anti-MAPK phospho (T202/Y240) rabbit 
polyclonal antibody (Cell Signaling Cat# 9101).  Total MAPK was detected by anti-
MAPK rabbit  polyclonal antibody (Cell signaling cat# 9102) that was then visualized by 
using anti-rabbit IgG (Amersham Lot# 387719) secondary antibody. Band quantification 
was done using Adobe Photoshop CS3 densitometry.  
 
Wound Healing ECIS:  
Wells of 8W10E+ plate(Applied Biophysics) were coated with 200µl 0.1% 
Gelatin per well for 30 minutes. Gelatin is then removed and wells are washed once with 
PBS. HUVEC cells are then seeded at 150,000 cells per well in the presence of 300µl of 
EGM.  Plate is placed in ECIS machine (Applied Biophysics) and monitored at 4000Hz, 
with readings taken every 30 seconds. After a monolayer is established EGM is removed, 
wells are washed carefully once with 300µl of PBS prior to addition of 300ul of EBM . 
Cells are allowed to starve in EBM overnight. The following day, cells are treated with 
respective conditions (FGF4	  and	  FGF2	  at	  1ng/ml,	  10ng/ml,	  and	  50ng/ml) with a final 
volume of 350µl and wounded immediately at voltage of 5V and a frequency of 
60000Hz.  
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Migration Assay:  
CIM plates (ACEA), consists of 2 chambers, were used to monitor migration.   
The lower chamber, each well receives 160µl of either FGF2 or FGF4 at one of the 
concentrations ( 1ng/ml, 5ng/ml, 15ng/ml) in EBM. Positive control wells received EGM 
and negative control wells received EBM only. After factors are placed in lower 
chamber, the two chambers are attached together and each well of the upper chamber 
receives 50µl of EBM. Plate is then placed in 37oC for 30 minutes. A total of 30,000 cells 
in 100µl of EBM are then seeded per well in upper chamber. Plates are placed in 
XCelligence RTADP (ACEA), system is blanked, then plate is removed and allowed to 
sit for 20 minutes are room temperature before placing the plates back in the XCelligence 
machine for data collection.  
 
 
Incucyte Cell PlayerTM:  
Ninety-six well plates were coated with 200 µl 0.1% gelatin for 30 minutes. Gelatin was 
removed and wells washed once with PBS. Cells are starved for four hours in the 
presence of EBM prior to seeding. Wells that had FGF4 received 40,000 cells well. Wells 
that contained FGF2 received 60, 000 cells per well.  Plate is then placed in Incucyte 
machine, and images are then taken every 2 hours using Incucyte technology (ESSEN 
BIOSCIENCE, Ann Arbor, Michigan). Pictures are analyzed by ImageJ to measure the 
area of the wound as time progressed.  
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Statistical Analyses 
  All graphs and statistical analysis are done using Prism. T-test analysis to test for 
significance is set at p<0.05. 	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RESULTS 	  
Western	  Blot	  Analysis-­‐	  First	  it	  is	  important	  to	  establish	  that	  the	  FGF2	  and	  4	  are	  active.	  Hence,	  their	  ability	  to	  bind	  to	  receptors	  on	  HUVECs	  as	  well	  as	  retain	  the	  ability	  to	  activate	  MAPK	  was	  tested	  using	  Western	  blot	  analysis.	  To	  do	  so,	  HUVEC	  cells	  were	  grown	  in	  endothelial	  growth	  media	  (EGM)	  until	  they	  reach	  80%	  confluence.	  The	  cells	  are	  then	  plated	  overnight,	  and	  starved	  for	  4	  hours	  the	  next	  day.	  Starvation	  is	  obtained	  by	  exchanging	  EGM	  with	  EBM	  for	  4hours.	  Cells	  are	  stimulated	  by	  FGF4	  at	  concentrations	  of	  1ng/ml,	  5ng/ml,	  10ng/ml	  and	  25ng/ml,	  and	  by	  FGF2	  at	  1ng/ml	  and	  5ng/ml.	  	  The	  Western	  blots	  are	  shown	  in	  Figure2	  and	  Figure4.	  In	  both	  instances,	  EBM	  resulted	  in	  a	  faint	  band,	  indicating	  very	  low	  activation.	  EGM	  on	  the	  other	  hand,	  cell	  lysates	  resulted	  in	  an	  intense	  band.	  	  In	  Figure2,	  FGF2	  at	  5ng/ml	  resulted	  in	  a	  more	  intense	  band	  than	  that	  at	  1ng/ml.	  For	  further	  assessment	  of	  signal	  intensity,	  bands	  where	  measured	  using	  Adobe	  Photoshop	  CS3	  densitometer.	  The	  values	  obtained	  for	  phMAPK	  is	  devided	  by	  that	  for	  total	  MAPK,	  and	  then	  graphed	  in	  the	  histogram	  relative	  to	  negative	  control.	  	  With	  FGF4	  (Figure4),	  however,	  it	  is	  not	  as	  simple	  to	  distinguish	  the	  band	  intensity	  between	  the	  different	  FGF4	  concentrations.	  Hence	  a	  measurement	  and	  calculation	  are	  done	  similar	  to	  FGF2And	  we	  generated	  a	  dose	  dependent	  curve	  (Figure	  5).	  The	  curve	  shows	  a	  sharp	  increase	  but	  then	  starts	  to	  slightly	  level	  off	  as	  concentration	  increases.	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Figure 2: Western Blot Analysis of the Effect of FGF2 on MAPK Activation in 
HUVEC Cells:  
 
HUVECs were starved for 4 hours then treated with 1ng/ml and 5ng/ml of FGF2 for 15 
minutes. A negative control is shown on the left (untreated in the presence of EBM). 
Bands in the top section are activated MAPK. Bands in the bottom section are the total 
MAPK. For a positive control the media was replaced  with EGM for full stimulation. 
50µg of total lysates was separated using NuPage 4-12% BisTris Midi Gel (Life 
Technologies Invitrogen), transferred onto polyvindylidene difluoride membrane using 
Invitrogen iBlot. Membrane is immunoblotted with anti-phosphotyrosine rabbit 
polyclonal antibody (phMAPK) to detect activated MAPK and with anti-MAPK rabbit 
polyclonal antibody MAPK) for detection of total MAPK. Secondary antibody used is 
anti-rabbit IgG monoclonal donkey antibody with horseradish conjugate.  
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Figure 3: Expression of phMAPK Over MAPK Relative to Control: 
White bar is EGM positive control. Pink bar is FGF2 1ng/ml and purple bar is FGF2 
5ng/ml.  Quantification of bands was obtained by Adobe Photoshop CS3 densitometry 
and is expressed relative to negative control.  
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Figure 4: Western Blot Analysis of the Effect of FGF4 on MAPK Activation in 
HUVEC Cells. 
HUVEC cells were starved for 4 hours then treated with 1ng/ml, 5ng/ml, 10ng/ml, and 
25ng/ml of FGF2 for 15 minutes. A negative control is shown on the left (untreated in the 
presence of EBM). Bands in the top section are activated MAPK. Bands in the bottom 
section are the total MAPK. For a positive control the media was replaced  with EGM for 
full stimulation. 50µg of total lysates was separated using NuPage 4-12% BisTris Midi 
Gel (Life Technologies Invitrogen), transferred onto polyvindylidene difluoride 
membrane using Invitrogen iBlot. Membrane is immunoblotted with anti-
phosphotyrosine rabbit polyclonal antibody (phMAPK) to detect activated MAPK and 
with anti-MAPK rabbit polyclonal antibody MAPK) for detection of total MAPK. 
Secondary antibody used is anti-rabbit IgG monoclonal donkey antibody with horseradish 
conjugate.  
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Figure 5: phMAPK activation by FGF4, Dose-response curve 
Quantification of the band intensity from Western blot using Adobe Photoshop and 
presented as a dose-dependent curve relative to negative control. Y-axis represents 
phMAPK/totalMAPK, and x-axis represents FGF4 concentrations.  
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Cell	  Migration	  Assay-­‐	  It	  has	  been	  demonstrated	  that	  FGF2	  has	  a	  chemotactic	  effect	  on	  HUVECs.	  FGF4	  on	  the	  other	  hand	  is	  a	  strong	  chemoattractant	  for	  embryonic	  streak	  cells.	  An	  ECIS	  migration	  assay	  was	  set	  up	  to	  study	  the	  effects	  of	  FGF4	  and	  FGF2	  on	  migration.	  The	  ECIS	  Migration	  Assay	  allowed	  us	  to	  monitor	  and	  quantify	  the	  ability	  of	  cells	  to	  migrate	  from	  upper	  chamber	  through	  a	  permeable	  membrane	  towards	  the	  factors	  in	  the	  lower	  chamber.	  HUVECs	  where	  starved	  overnight	  before	  the	  assay	  to	  elicit	  a	  faster	  migratory	  response	  and	  to	  eliminate	  any	  factors	  that	  could	  be	  in	  the	  system	  that	  would	  cause	  a	  nonspecific	  migratory	  response	  other	  than	  the	  added	  FGFs.	  	  In	  Figure6,	  FGF4	  at	  5ng/ml	  resulted	  in	  better	  migration	  compared	  to	  FGF4	  at	  concentration	  of	  15	  ng/ml.	  FGF2	  migration	  assay	  with	  the	  same	  concentration	  (Figure	  7)	  resulted	  in	  similar	  outcomes	  where	  at	  5ng/ml,	  cells	  migrated	  better	  than	  at	  15ng/ml.	  In	  order	  to	  identify	  the	  concentration	  that	  would	  result	  in	  optimal	  migratory	  response,	  another	  set	  of	  experiments	  (Figure	  8	  and	  Figure	  9)	  was	  conducted	  at	  concentrations	  of	  5ng/ml	  and	  1ng/ml	  for	  each	  of	  the	  two	  factors.	  However,	  FGF4	  and	  FGF2	  at	  1ng/ml	  resulted	  in	  a	  lower	  migratory	  response	  that	  when	  cells	  are	  induce	  with	  5ng/ml	  of	  FGF2	  or	  4.	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Figure 6. Effects of FGF4 5ng/ml and 15ng/ml on HUVECS Migration 
 HUVEC migration due to FGF4 at two concentrations, 5ng/ml and 15ng/ml are shown. 
Cells were starved for 16 hours prior analysis. Data was normalized value/baseline. EGM 
in red acts as a positive control. EBM in blue acts as a negative Control. 
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Figure 7. Effects of FGF2 5ng/ml and 15ng/ml on HUVECS Migration 
HUVEC migration due to FGF2 at two concentrations, 5ng/ml and 15ng/ml are shown. 
Cells were starved for 16 hours prior analysis. Data was normalized value/baseline. EGM 
in red acts as a positive control. EBM in blue acts as a negative Control. 
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Figure	  8:	  Effects	  of	  FGF4	  1ng/ml	  and	  5ng/ml	  on	  migration	  HUVEC	  migration	  due	  to	  FGF4	  at	  two	  concentrations,	  5ng/ml	  and	  1ng/ml	  are	  shown.	  Cells	  were	  starved	  for	  16	  hours	  prior	  analysis.	  Data	  was	  normalized	  to	  base	  line	  value.	  EGM	  in	  red	  acts	  as	  a	  positive	  control.	  EBM	  in	  blue	  acts	  as	  a	  negative	  Control.	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Figure	  9:	  Effects	  of	  FGF2	  1ng/ml	  and	  5ng/ml	  on	  migration	  HUVEC	  migration	  due	  to	  FGF2	  at	  two	  concentrations,	  5ng/ml	  and	  1ng/ml	  are	  shown.	  Cells	  were	  starved	  for	  16	  hours	  prior	  analysis.	  Data	  was	  normalized	  to	  base	  line	  value.	  EGM	  in	  red	  acts	  as	  a	  positive	  control.	  EBM	  in	  blue	  acts	  as	  a	  negative	  Control	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   Wound	  Healing	  ECIS	  Assay-­‐	  To	  test	  the	  effects	  of	  FGF2	  and	  FGF4	  on	  motility	  and	  ability	  to	  move	  into	  empty	  areas	  and	  heal	  a	  wounded	  monolayer,	  an	  ECIS	  Wound	  Healing	  Assay	  was	  designed.	  HUVECs	  where	  grown	  in	  the	  presence	  of	  EGM	  until	  they	  reached	  90%	  confluence.	  Wells	  in	  EW10E+	  plates	  were	  treated	  with	  0.1%	  gelatin	  for	  30	  minutes.	  Gelatin	  was	  then	  removed	  and	  wells	  were	  washed	  with	  PBS	  .	  A	  total	  of	  150,000	  cells	  were	  placed	  in	  each	  well	  with	  300µl	  EGM	  for	  24	  hours	  until	  monolayers	  are	  formed.	  EGM	  was	  then	  removed	  and	  washed	  once	  with	  PBS	  carefully	  without	  disturbing	  the	  monolayer.	  Cells	  were	  starved	  for	  16	  hours	  in	  the	  presence	  of	  EBM.	  After	  16	  hours,	  the	  EBM	  was	  replaced	  by	  EGM.	  FGFs	  were	  add	  in	  a	  volume	  of	  50µl	  added	  to	  the	  existent	  300µl	  EBM	  to	  make	  a	  total	  volume	  of	  350µl.	  Three	  concentrations	  where	  used	  for	  each	  of	  the	  two	  FGFs,	  1ng/ml,	  10ng/ml,	  and	  50ng/ml.	  	  	  Figures	  10	  and	  11	  illustrate	  the	  wound-­‐healing	  curve	  of	  FGF4	  and	  FGF2	  respectively.	  All	  wells	  recovered	  back	  to	  the	  starting	  point.	  Different	  factors	  at	  different	  concentrations	  however	  exhibited	  different	  rates	  of	  recovery.	  Slopes	  (Figure	  12)	  of	  the	  rise	  of	  the	  curves	  were	  calculated	  between	  the	  bases	  of	  the	  curve	  as	  it	  starts	  to	  rise	  and	  as	  it	  plateaus.	  	  	   In	  both	  FGF2	  and	  FGF4,	  cells	  responded	  to	  the	  stimulus	  in	  a	  dose	  dependent	  manner.	  Cells	  that	  received	  either	  one	  of	  the	  factors	  at	  a	  concentration	  of	  1ng/ml	  had	  the	  slowest	  recovery,	  while	  cells	  that	  received	  a	  concentration	  of	  50ng/ml	  had	  the	  highest	  recovery	  rate.	  However,	  the	  magnitude	  by	  which	  the	  slope	  increases	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from	  1ng/ml	  to	  10ng/ml	  is	  not	  the	  same	  of	  that	  when	  the	  concentration	  increases	  from	  10ng/ml	  to	  50ng/ml.	  	  Moreover,	  FGF2	  had	  a	  slightly	  higher	  recovery	  rate	  at	  10ng/ml	  and	  50ng/ml	  than	  FGF4	  at	  these	  same	  concentrations.	  However,	  FGF4	  had	  a	  higher	  recovery	  rate	  at	  1ng/ml	  than	  FGF2	  at	  that	  same	  concentration.	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Figure 10: Effects of FGF4 on HUVECs Wound Healing Using ECIS  
Wound healing curve of HUVEC cells as a result of FGF4. Three FGF4 concentrations 
were used, 1ng/ml, 10ng/ml and 50 ng/ml. Measurements are completed by measuring 
the resistance through gold wires that pass through the wells. When a monolayer is 
established, resistance rises and a plateau is reached. As the monolayer is wounded, 
resistance drops at least by 80%. 
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Figure 11: Effects of FGF2 on Wound Healing using ECIS 
Wound healing curve of HUVEC cells as a result of exposure to FGF2. Three FGF2 
concentrations were used, 1ng/ml, 10ng/ml and 50ng/ml. Measurement were performed 
by measuring the resistance through gold wires that pass through the wells. When a 
monolayer is established, resistance rises and a plateau is reached. As the monolayer is 
wounded, resistance drops at least  by 80%. 
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Figure 12: Rate of Wound Recovery. 
Shown is the slope of recovery back to monolayer. This represents the rate or speed at 
which HUVEC cells grow back into the wounded area to form a monolayer once again. 
The histogram is normalized to EBM. A t-test was used to check for significance between 
cell that received EBM only (negative control) and those that received FGFs. * and ** 
indicate p<0.05 and 0.01 respectively.  
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Incucyte- To supplement our data from the ECIS Wound Healing Assay, we used 
Incucyte technology. Incucyte provided a real time lapse microscopy, that allowed us to 
have a visual of cells as time passes. This allowed us to manually identify the wound and 
calculate its area using ImageJ for every time point. In Figure 13, contains two of the 
time points, at 0hr and at 20 hr or last time point. The areas of the time points are 
represented in Figures 14 and 15 for FGF4 and FGF2 respectively. FGF4 had a more 
dramatic effect as we move up with the concentration versus FGF2. FGF4 had a dose 
dependent response on HUVEC cells. FGF2 on the other hand did not have dramatic 
changes between the two concentrations of 1ng/ml and 10ng/ml. when cells were 
stimulated with FGF4 at 10ng/ml they close more than 70% of the wound; however, 
when they were stimulated by the same amount of FGF2, cells closed less than 50% of 
the wound (Figure 15).  
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Figure 13. Time-lapse Microscopy Using Incucyte 
Pictures were taken ever 2hrs by incucyte. White boarder outlines open wound area.  
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Figure 14: Effects of FGF4 on Wound Closure using Incucyte   
HUVECs seeded on 0.1% gelatin in 96-well plate wells were scratched creating a wound. 
Different concentrations of FGF4 were added and wound closure by the cells was 
monitored. Pictures where taken every two hours. With ImageJ, the area of the wound 
was calculated and plotted as a function of time. EGM showed the highest and fastest 
wound healing. Wells that were stimulated by FGF4 reacted in a dose dependent manner. 
Cells receiving 10ng/ml closed the wound the most, followed by 3ng/ml and 1ng/ml, 
respectively. 
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Figure 15. Effects of FGF2 on Wound Closure using Incucyte 
HUVECs seeded on 0.1% gelatin in 96-well plate wells were scratched creating a wound. 
Different concentrations of FGF2 was added and wound closure by the cells was 
monitored. Pictures where taken every two hours. With Imagej, the area of the wound 
was calculated and plotted as a function of time. EGM showed the highest and fastest 
wound healing. Wells that were stimulated by FGF2 reacted in a dose dependent manner. 
Cells receiving 1ng/ml closed the wound the most, followed by 10ng/ml. 
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Figure 16: Percentage of Wound Closure 
Using ImageJ, the area of  the open wound was taken at the t=0hr and at t=10hrs. The 
difference amongst the measurements was taken for each condition. The percentage 
wound closure at t=10hr was then calculated. 
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DISCUSSION 	  
FGF2 and FGF4 are involved in a wide variety of cellular processes such as cell 
migration, wound healing, and angiogenesis. In aberrant levels, they contribute to 
pathologies such as in different types of cancers and atherosclerosis. In this study, 
HUVECs were used as a model to study the effects of FGF2 and FGF4 activity on 
migration and wound healing. It has been reported the FGF2 and FGF4 elicit a migratory 
and wound healing responses in cells, but to the best of my knowledge, no one has 
demonstrated these effects on HUVECs using our system.  
FGFs activate cells through a MAPK pathway by binding to FGFRs found on the 
surfaces of cells. FGF4 appears to activate MAPK in a dose-dependent fashion (Figure5). 
However it appears that as the concentration reaches 25ng/ml of FGF4, MAPK activation 
starts to level off. This might suggest that receptors on HUVECS are starting to saturate 
with FGF4. FGF2 also activated more MAPK at a higher concentration of 10ng/ml versus 
1ng/ml (Figure3).  
The activation of MAPK by FGF2 (Figure 2) and FGF4 (Figure3) indicated that 
they are able to bind and activate HUVEC cells. This indicated the presence of FGFR on 
the surface of HUVECs.  
To assess the effect of MAPK activation via FGF2 and FGF4 on migration, we 
used the ECIS Migration Assay. CIM plates used in this assay consist of two chambers, 
i.e. the upper that will contain cells and lower that will contain the factors. A permeable 
membrane separates the two chambers. Cell will have to sense the presence of the factors 
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and migrate to the other side of the membrane. With HUVECs responded to the different 
concentrations of the FGF2 and FGF4 in bell curve fashion. Cells showed low migratory 
response to FGF2 and FGF4 when they where used at a concentration of 1ng/ml and 
15ng/ml. However, HUVECs started to migrate at 5ng/ml. This indicates that HUVECs 
in this assay are very sensitive to small changes in FGF2 and FGF4 concentrations.  
FGF2 and FGF4 ability to induce wound healing and motility was investigated 
using the ECIS Wound Healing Assay and Incucyte. With the ECIS Wound Healing 
Assay we used 8W10E+ plates that contain 40 electrodes per well. Electrodes measure 
the resistance in the well created by the cells’ monolayer formation. When the monolayer 
is wounded by a passage of electric current, the resistance drops. The ECIS machine then 
records the resistance as cells move in covering the wounded areas.  
When the rate of recovery was calculate (figure 12), HUVECs showed a dose-
dependent response with both factors. FGF2 had a faster recovery rate FGF4 at 10ng/ml 
and 50ng/ml. FGF4 has a higher recovery rate than FGF2 when compared at 1ng/ml. This 
could suggest that HUVECs activation saturates at a lower dose than that with FGF4.  
 Incucyte technology was also used to attain visual and cell activity during wound 
healing as a result of FGF2 and FGF4. In the Incucyte, unlike the ECIS wound-healing 
assay, a manual scratcher supplied by the manufacturer generated the wound. The wound 
was analyzed by measuring the area as a function of time. FGF4 elicits a dose-dependent 
response with concentration of 10ng/ml inducing HUVECs to move in more than 70% of 
the wound (Figure14 and Figure16). FGF2, however, did not generate such a result (less 
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the 50% of the wound was closed). In fact with FGF2, 1ng/ml has a slightly higher 
wound closure (Figure15 and Figure16).  
 Results from Incucyte and ECIS Wound healing illustrates the different out comes 
each assay generates using HUVECs. However, both assays show that FGF2 and FGF4 
induce HUVECs to move in wounded areas.   
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CONCLUSION 
 
 In these series of experiments, we established a model using HUVECs cell in 
order to study cellular and molecular effects of FGF2 and FGF4.  We have demonstrated 
that FGF2 and FGF4 both activate MAPK in HUVECs. We also showed that these 
factors induce migration using ECIS in addition to wound healing through Incucyte and 
ECIS Wound healing Assays. We have also observed differences in induction between 
FGF2 and FGF4 on cellular mechanism. Using ECIS wound healing, FGF2 showed a 
higher induction while in Incucyte FGF4 had the higher induction. This suggests that 
FGF2 and FGF4 affect different molecular entities that affect wound healing and motility 
differently.    
This series of experiments could serve as an optimized foundation to proceed 
forward in additional investigation on FGF2 and FGF4 modulation by BP1 and BP3 and 
the affects cellular response.  
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